Decentralized clinical trials (DCTs) have been central to the continuation of vital clinical studies throughout the COVID-19 pandemic. Previously the uptake of decentralized models has been slow, but the pandemic changed this. There is now consensus among industry leaders that DCTs are here to stay and may have a central role in advancing research especially in rare diseases. In this article we look at the benefits and challenges of DCTs.
Traditional clinical trials place a significant burden on patients and their caregivers in terms of time and travel. Decentralized clinical trials offer an alternative model of trial participation and have several advantages over traditional, site-based clinical trials.
However, DCTs also present challenges as they require the correct infrastructure and regulatory environment.
The COVID-19 pandemic forced investigators and sponsors to rapidly adapt how they conducted clinical trials leading to the implementation of telemedicine, remote patient monitoring, and electronic medical record tools. While DCTs may not replace traditional models they offer great potential for helping to address the issue of patient recruitment especially in rare diseases affecting small populations across wide geographic areas. DCTs may help with patient retention by effectively bringing the trial to them and so reducing accessibility and travel burdens. Harnessing digital technologies may also improve data quality as data collection can be continuous throughout studies. It therefore seems likely that DCTs are here to stay and will be used particularly in specific therapeutic areas.
[i] Shikova D. The Benefits and Barriers of Decentralized Clinical Trials. TrialHub website. Updated August 11, 2020. https://trialhub.findmecure.com/blog/the-benefits-and-barriers-of-decentralized-clinical-trials/.
Tuesday 1 December marked World AIDS Day 2020. Although throughout this year our focus has been on the coronavirus pandemic, World AIDS Day is an opportunity to reflect on another pandemic where a virus passed from animals to humans with devastating consequences. To date 77 million people worldwide have been infected with HIV. In spite of innovative new treatments 35 million people have died from the virus.
If you missed the live webinar “Where in the world should I locate my pivotal clinical trial?” you can now watch the recording by clicking here. The webinar hosted by the Society of Physician Entrepreneurs (SoPE) and Workforce Genetics features Cromos Pharma's CEO Vlad Bogin, M.D, FACP.